SecBot SecBot
PRESS-RELEASE ·Filed Apr 30, 2026

DBVT

DBV Technologies S.A.
BULLISH
Impact 5/10
Horizonimmediate Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The earnings beat and strong cash position support the upcoming BLA filing. Monitor regulatory updates and potential FDA approval catalyst for VIASKIN Peanut Patch.

DirectionBullish
Confidencemedium
Horizonimmediate
Final — all horizons settled through T+60d
DBVT ▼ -32.06% at T+60d
LONG call ✗ call lost -32.06% · α vs SPY -35.13% · entry $19.87 → $13.50
Entry = T+0 close
Apr 30, 2026
via day close
T+1d
-2.01%
call -2.01% · α -1.67%
$19.47
settled 6mo ago
T+5d
-0.70%
call -0.70% · α -3.05%
$19.73
settled 6mo ago
T+20d
-5.38%
call -5.38% · α -10.65%
$18.80
settled 5mo ago
T+60d
-32.06%
call -32.06% · α -35.13%
$13.50
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

DBV Technologies reported Q1 2026 EPS of $(0.11), beating consensus of $(0.12) by 8.3%, and revenue of $0.9M, beating $819K consensus by 9.9%. The company maintains a strong cash position of $229M, funding operations into Q2 2027, and reiterates its plan to submit a BLA for the VIASKIN Peanut Patch in the first half of 2026.

Key Financial Metrics

EPS
−$0.11
est −$0.12 · +8.3%
Revenue
$900.0K
est $819.0K · +9.9% · +12.5% YoY
Rating
beat

Key Facts

  • Q1 2026 EPS $(0.11) vs consensus $(0.12) (beat by 8.3%)
  • Q1 2026 revenue $0.9M vs consensus $819K (beat by 9.9%)
  • Net loss widened to $47.6M from $27.1M year-over-year, but per-share loss improved due to higher share count
  • Cash and cash equivalents $229M as of March 31, 2026, up from $194M at year-end 2025
  • Cash runway into Q2 2027; BLA submission for VIASKIN Peanut Patch (ages 4-7) planned H1 2026

Financial Impact

EPS beat by $0.01 and revenue beat by $81K; net loss increased by $20.5M YoY

epsrevenuenet losscash

Risk Factors

  • BLA submission or approval delays
  • Continued operating losses and cash burn
  • Commercialization risks if approved

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3285516
7 reports for DBVT
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for DBVT — sortable, filterable
TypeNow
Sep 29, 2026
28d ago
8-K
BULLISH ★ 7/10
$11.76 $9.77▼ −16.92%▼ −18.83%$10.13 (−13.90%)
Jul 27, 2026
13w ago
S-3ASR
BEARISH ★ 6/10
$13.90 $13.50▲ +2.88%▲ +3.95%$10.13 (+27.16%)
Jul 6, 2026
16w ago
Press Release
NEUTRAL ★ 2/10
$17.35 $15.92▼ −8.24%▼ −8.79%$10.13 (−41.64%)
Jun 29, 2026
17w ago
8-K
NEUTRAL ★ 5/10
$16.40 $15.61▼ −4.82%▼ −5.42%$10.13 (−38.26%)
Apr 30, 2026
25w ago
Press Release
BULLISH ★ 5/10
$19.87 $19.73▼ −0.70%▼ −3.05%$10.13 (−49.04%)
Mar 26, 2026
30w ago
Press Release
NEUTRAL ★ 3/10
$20.00 $20.36▲ +1.80%▼ −2.06%$10.13 (−49.38%)
Mar 26, 2026
30w ago
Press Release
MIXED ★ 6/10
$20.00 $20.36▲ +1.80%▼ −2.06%$10.13 (−49.38%)
Showing 7 of 7

US Market Status

Market Closed — Opens in 8h 26m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026